New Zealand: Progress toward New Zealand's new Patents Act - end of year report card

Last Updated: 23 December 2012
Article by Mark Vincent and Gareth Dixon

"Has progressed in fits-and-starts. A more consistent effort may be beneficial. For now, may have been consigned to the too-hard basket".

As readers will know, New Zealand patent law has been in the throes of reform for the best part of a decade. The original exposure draft of the Patents Bill was released in 2004 – and since that time, we've penned a series of very similar articles, each entitled something along the lines of "Progress Toward New Zealand's New Patents Act". Of course, the term "progress" has been somewhat subjective. More than eight years have elapsed – and we're still waiting for the new legislation to be passed.

As 2012 began, the current draft legislation (the Patents Bill 2008) had been dormant for nearly three years. Whilst it remained on the Parliamentary Agenda, it had slipped as low as #55. As such, we didn't expect much progress to be made during 2012 – passage of the Bill seemed to have been consigned to the "too-hard basket".

Perhaps that's a little harsh – for as we'll see in this article, there may be good reasons why the Bill appeared to have gone "nowhere fast". On the other hand, no such reason can obscure the fact that New Zealand's current patents legislation is based on the 1949 UK Patents Act – which, as we all know, was itself replaced nearly four decades ago. Of course, the world is a vastly different place to what it was at the end of World War II – and the social, political and economic rationale for replacing New Zealand's antiquated patents legislation are well known and widely accepted.

Unfortunately, we had a situation where the desirability of a new Patents Act was in effect, being overshadowed by the difficulties faced in achieving it – indeed, material ripe for the "too-hard basket"...

Fast-forward to August 2012 – and the New Zealand Government released its "Building Innovation" Report (see, our article: The net effect of this Report was that patents were suddenly "in vogue" – and the Patents Bill 2008 got the "shot in the arm" that it needed to move to the front of the Parliamentary Agenda.

In line with one of the stated objectives of the Report, the Bill had its second Parliamentary Reading on 12 September 2012. Unfortunately, that's not so much where the problems end as it is where they begin – and somewhat ironically, the Bill is probably now further from being passed into law than it was prior to this second Reading(!) Although the Bill was approved by a clear majority of the House, to assume that there was a majority consensus as to its content (especially as it relates to software patents) would be incorrect.

As we've reported on previously (see, e.g.,, perhaps the most controversial aspect of the draft legislation is the issue of whether or not software patents would be "in", "out" – or something in between.

In this respect, the New Zealand Government has somewhat "cast a rod for its own back"; the Government must now adopt a strong position where previously it had been weak. After initially (back in 2004, with the Exposure Draft of the Patents Bill) proposing to allow software patents, the Government then bowed down to a well organised anti-software lobby during the public consultation process; a blanket exclusion on software patents was proposed. However, whilst popular with proponents of open-source software, the proposed exclusion had two principal shortcomings: Article 27 of TRIPs – and background negotiations toward a Free Trade Agreement (FTA) with the United States (who would obviously insist on software patents being made available). When the Bill re-emerged from its three year slumber, three Supplementary Order Papers were then tabled – each proposing a different form of the software "exclusion" (see, our article:

The Bill has now been referred to a Select Committee of the Full House, who will no doubt debate the software conundrum and decide, once and for all, where New Zealand stands on this issue. This debate has hovered at around #20 on the Parliamentary Agenda for the past couple of months. Has it genuinely been consigned to the "too-hard basket" – or is there something else going on in the background?

As with most situations, the answer is probably "a little bit of both". Certainly, the software issue is going to be difficult to resolve during the Committee stage – especially given that the (Conservative) Government lacks a clear majority over a coalition of opposition parties and "crossbenchers".

However, as touched upon earlier, given the background negotiations with the United States (and others) toward a Free Trade Agreement, perhaps it is prudent on the Government's behalf to defer for a while – and consider the requirements of any FTA if/when it is agreed upon.

By way of a brief history, back in February 2008, the US announced that it would attempt joining negotiations with four Asia-Pacific countries: New Zealand, Singapore, Brunei and Chile (the "P4"), with a view to "gatecrashing" their negotiations toward the "Trans-Pacific Strategic Economic Partnership".

Whilst in theory, the opportunity to trade freely with the US would be a boon for the P4 countries, any such multilateral free trade agreement will inevitably come at a price; New Zealand would likely need to yield in certain areas in order to secure such a deal. With this in mind, the US Government publishes an annual report entitled "Foreign Trade Barriers", in which it particularises laws and regulatory mechanisms of foreign countries that are considered significant barriers to US exports. In this document, US pharmaceutical companies have identified New Zealand's lack of pharmaceutical extension as being an impediment to trade.

In New Zealand, pharmaceutical extension of term was the subject of a governmental review dating back to a discussion paper released in June 2003. When all the "pros and cons" were considered, the New Zealand Government opted against enacting a pharmaceutical extension provision on the basis of its economic impact on consumers – and this is the side on which New Zealand's "line in the sand" has been presumed to lie (note: the situation is very different in Australia).

However, given the lobbying power of the "big pharma", the chances of the pharmaceutical extension issue appearing at the US-P4 negotiating table would appear somewhat "real". In the extreme, this could see New Zealand patent law aligned for compatibility with 35 USC 155 and 156, so that US "big pharma" are able to maintain their New Zealand patents for longer, and in turn, make greater profits. The trade-off, of course, is that the New Zealand consumer, who would then be required to pay more for healthcare, is afforded greater access to the US marketplace (which includes the highly-lucrative US dairy industry). In terms of NZ's "bargaining chips" toward the FTA, pharmaceutical extension is likely to be high on the list.

Of course, such a concession is unlikely to be well received by the New Zealand public. In this respect, the Pharmaceutical Management Agency ("Pharmac") in the authority charged with selecting which drugs are subsidised by the New Zealand Government; they generally opt for cheaper generics where possible. Any extension of term will obviously delay the availability of generics onto the New Zealand market, with the net effect that certain medicines will be more expensive – and for longer. It goes without saying that such a concession is unlikely to win the Government votes come election time.

In the interim, just as the Patents Bill 2008 currently sits idle, so too does the P4 Agreement. However, several countries have recently joined, or are considering joining. Australia, Canada, Peru, Vietnam, Malaysia and Mexico are in the former group; South Korea, Japan, Taiwan and the Philippines are in the latter. Although President Obama seemed keen to settle negotiations at last year's APEC Summit, the fifteenth round of negotiations recently concluded in Auckland. Is it mere coincidence that the Patents Bill 2008 (with no extension of term) again seems to have stalled while the "P4+" negotiations rumble on? We think not.

As mentioned, New Zealand had previously decided against a pharmaceutical extension on the basis of its economic impact on local consumers. However, with a potential US-NZ FTA at stake, it is possible that the Patents Bill 2008 may yet undergo one or two changes before it is passed into law. However, if there's one thing we've learnt since 2004, when the first draft of the Patents Bill was released, it's to not hold our breath...

As an aside, one of the other especially controversial aspects of the US-P4 negotiations as they pertain to intellectual property appears to be the extent to which alleged copyright infringers are able to be extradited and/or prosecuted when they are domiciled abroad. In this respect, the "MegaUpload/Kim Dotcom" case has assumed almost cult-like status throughout Australasia (see, our article: As things stand, Mr Dotcom's extradition from New Zealand to the United States is by no means certain, whereas if the US-P4 FTA were signed tomorrow, the situation would be largely reversed.

To conclude, I'd like to offer my personal thanks to those who have read (and perhaps commented) on my articles throughout 2012. Sincere best wishes for the holiday season – and I look forward to working with you again in 2013.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions